Skip to Content

AEterna Zentaris Inc AEZS

Morningstar Rating
$8.52 −0.07 (0.77%)
View Full Chart
Unlock our analysis with Morningstar Investor

About Quantitative Ratings

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.

Price vs Fair Value

AEZS is trading at a 462% premium.
Price
$8.42
Fair Value
$78.19
Uncertainty
Extreme
1-Star Price
$123.62
5-Star Price
$7.36
Economic Moat
Qmrj
Capital Allocation
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if AEZS is a good fit for your portfolio.

News

Trading Information

Previous Close Price
$8.59
Day Range
$8.518.68
52-Week Range
$5.4412.80
Bid/Ask
$8.50 / $8.67
Market Cap
$10.34 Mil
Volume/Avg
5,648 / 6,096

Key Statistics

Price/Earnings (Normalized)
Price/Sales
4.36
Dividend Yield (Trailing)
Dividend Yield (Forward)
Total Yield

Company Profile

AEterna Zentaris Inc is a biopharmaceutical company commercializing & developing therapeutics & diagnostic tests. The company's product, Macrilen (macimorelin), is the oral test indicated for the diagnosis of adult growth hormone deficiency (GHD). Macrilen is marketed in the U.S. through a license agreement with Novo Nordisk & the company receives royalties on sales. Aeterna owns all rights to macimorelin outside of the U.S. & Canada. It is leveraging the clinical success & safety profile of macimorelin to develop it for the diagnosis of child-onset GHD. The company's geographical segments include Switzerland which generates key revenue, Ireland, Denmark, and others.
Sector
Healthcare
Industry
Biotechnology
Stock Style Box
Small Value
Total Number of Employees
24

Valuation

Metric
AEZS
Price/Earnings (Normalized)
Price/Book Value
1.31
Price/Sales
4.36
Price/Cash Flow
Price/Earnings
AEZS

Financial Strength

Metric
AEZS
Quick Ratio
5.68
Current Ratio
5.94
Interest Coverage
Quick Ratio
AEZS

Profitability

Metric
AEZS
Return on Assets (Normalized)
−35.86%
Return on Equity (Normalized)
−337.80%
Return on Invested Capital (Normalized)
−63.03%
Return on Assets
AEZS
See how this stock stacks up to its competitors with Morningstar Investor

Biotechnology Industry Comparables

Ticker
Name
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
NVO
Novo Nordisk A/S ADRSsqthrpgtCvfky$586.1 Bil
VRTX
Vertex Pharmaceuticals IncSwjcbmyqVcwjhdr$113.7 Bil
REGN
Regeneron Pharmaceuticals IncQpzjkvcdJftgtrk$108.2 Bil
MRNA
Moderna IncXmvbfmgzGmky$50.9 Bil
ARGX
argenx SE ADRYgyxqjlzkBkv$22.0 Bil
BNTX
BioNTech SE ADRByszlykCjk$21.8 Bil
ALNY
Alnylam Pharmaceuticals IncHflfwrwBxvyqy$18.9 Bil
BMRN
Biomarin Pharmaceutical IncRgmbldmwSqwskc$14.6 Bil
INCY
Incyte CorpPnzdggmSwpkwz$12.8 Bil
RPRX
Royalty Pharma PLC Class ASktdznssWfzrln$12.3 Bil

Sponsor Center